Medical - Care Facilities
Compare Stocks
5 / 10Stock Comparison
ASTH vs AGL vs ALHC vs HUM vs UNH
Revenue, margins, valuation, and 5-year total return — side by side.
Medical - Care Facilities
Medical - Healthcare Plans
Medical - Healthcare Plans
Medical - Healthcare Plans
ASTH vs AGL vs ALHC vs HUM vs UNH — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | |||||
|---|---|---|---|---|---|
| Industry | Medical - Care Facilities | Medical - Care Facilities | Medical - Healthcare Plans | Medical - Healthcare Plans | Medical - Healthcare Plans |
| Market Cap | $2.19B | $905M | $3.66B | $33.01B | $344.90B |
| Revenue (TTM) | $3.53B | $5.82B | $4.26B | $137.20B | $449.71B |
| Net Income (TTM) | $30M | $-373M | $20M | $1.13B | $12.04B |
| Gross Margin | 6.8% | -3.7% | 9.0% | 14.0% | 18.8% |
| Operating Margin | 2.5% | -6.9% | 0.8% | 1.0% | 4.2% |
| Forward P/E | 31.0x | — | 101.8x | 30.8x | 20.7x |
| Total Debt | $1.08B | $37M | $338M | $12.94B | $78.39B |
| Cash & Equiv. | $429M | $174M | $578M | $4.20B | $24.36B |
ASTH vs AGL vs ALHC vs HUM vs UNH — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | Apr 21 | May 26 | Return |
|---|---|---|---|
| Astrana Health, Inc. (ASTH) | 100 | 132.4 | +32.4% |
| Agilon Health, Inc. (AGL) | 100 | 6.9 | -93.1% |
| Alignment Healthcar… (ALHC) | 100 | 67.6 | -32.4% |
| Humana Inc. (HUM) | 100 | 61.8 | -38.2% |
| UnitedHealth Group … (UNH) | 100 | 95.3 | -4.7% |
Price return only. Dividends and distributions are not included.
Quick Verdict: ASTH vs AGL vs ALHC vs HUM vs UNH
Each card shows where this stock fits in a portfolio — not just who wins on paper.
ASTH is the #2 pick in this set and the best alternative if long-term compounding is your priority.
- 6.8% 10Y total return vs UNH's 228.3%
- 56.4% revenue growth vs AGL's -2.1%
- +17.5% vs AGL's -32.6%
AGL plays a supporting role in this comparison — it may shine differently against other peers.
ALHC is the clearest fit if your priority is growth exposure.
- Rev growth 46.1%, EPS growth 99.4%, 3Y rev CAGR 40.2%
Among these 5 stocks, HUM doesn't own a clear edge in any measured category.
UNH carries the broadest edge in this set and is the clearest fit for income & stability and sleep-well-at-night.
- Dividend streak 25 yrs, beta 0.60, yield 2.3%
- Lower volatility, beta 0.60, Low D/E 77.1%, current ratio 0.79x
- Beta 0.60, yield 2.3%, current ratio 0.79x
- Lower P/E (20.7x vs 101.8x)
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 56.4% revenue growth vs AGL's -2.1% | |
| Value | Lower P/E (20.7x vs 101.8x) | |
| Quality / Margins | 2.7% margin vs AGL's -6.4% | |
| Stability / Safety | Beta 0.60 vs AGL's 3.07 | |
| Dividends | 2.3% yield, 25-year raise streak, vs ASTH's 0.4%, (2 stocks pay no dividend) | |
| Momentum (1Y) | +17.5% vs AGL's -32.6% | |
| Efficiency (ROA) | 3.9% ROA vs AGL's -24.5%, ROIC 9.2% vs -203.2% |
ASTH vs AGL vs ALHC vs HUM vs UNH — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
ASTH vs AGL vs ALHC vs HUM vs UNH — Financial Metrics
Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
UNH leads in 4 of 6 categories
ASTH leads 1 • AGL leads 0 • ALHC leads 0 • HUM leads 0 • 1 tied
Explore the data ↓Income & Cash Flow (Last 12 Months)
UNH leads this category, winning 3 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
UNH is the larger business by revenue, generating $449.7B annually — 127.5x ASTH's $3.5B. UNH is the more profitable business, keeping 2.7% of every revenue dollar as net income compared to AGL's -6.4%. On growth, ASTH holds the edge at +55.6% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | |||||
|---|---|---|---|---|---|
| RevenueTrailing 12 months | $3.5B | $5.8B | $4.3B | $137.2B | $449.7B |
| EBITDAEarnings before interest/tax | $141M | -$371M | $66M | $2.2B | $23.2B |
| Net IncomeAfter-tax profit | $30M | -$373M | $20M | $1.1B | $12.0B |
| Free Cash FlowCash after capex | $155M | -$77M | $237M | $1.3B | $19.7B |
| Gross MarginGross profit ÷ Revenue | +6.8% | -3.7% | +9.0% | +14.0% | +18.8% |
| Operating MarginEBIT ÷ Revenue | +2.5% | -6.9% | +0.8% | +1.0% | +4.2% |
| Net MarginNet income ÷ Revenue | +0.9% | -6.4% | +0.5% | +0.8% | +2.7% |
| FCF MarginFCF ÷ Revenue | +4.4% | -1.3% | +5.6% | +0.9% | +4.4% |
| Rev. Growth (YoY)Latest quarter vs prior year | +55.6% | -7.3% | +33.3% | +23.5% | +2.0% |
| EPS Growth (YoY)Latest quarter vs prior year | +107.1% | +140.0% | +2.1% | -4.6% | +0.7% |
Valuation Metrics
UNH leads this category, winning 2 of 6 comparable metrics.
Valuation Metrics
At 27.9x trailing earnings, HUM trades at a 67% valuation discount to ASTH's 85.4x P/E. On an enterprise value basis, UNH's 17.1x EV/EBITDA is more attractive than ALHC's 75.7x.
| Metric | |||||
|---|---|---|---|---|---|
| Market CapShares × price | $2.2B | $905M | $3.7B | $33.0B | $344.9B |
| Enterprise ValueMkt cap + debt − cash | $2.8B | $768M | $3.4B | $41.7B | $398.9B |
| Trailing P/EPrice ÷ TTM EPS | 85.43x | -2.21x | -4845.95x | 27.94x | 28.72x |
| Forward P/EPrice ÷ next-FY EPS est. | 31.03x | — | 101.82x | 30.77x | 20.71x |
| PEG RatioP/E ÷ EPS growth rate | — | — | — | — | — |
| EV / EBITDAEnterprise value multiple | 22.84x | — | 75.68x | 18.34x | 17.10x |
| Price / SalesMarket cap ÷ Revenue | 0.69x | 0.15x | 0.93x | 0.25x | 0.77x |
| Price / BookPrice ÷ Book value/share | 3.48x | 7.09x | 19.80x | 1.87x | 3.40x |
| Price / FCFMarket cap ÷ FCF | 20.95x | — | 32.37x | 88.03x | 21.46x |
Profitability & Efficiency
UNH leads this category, winning 6 of 9 comparable metrics.
Profitability & Efficiency
UNH delivers a 11.5% return on equity — every $100 of shareholder capital generates $12 in annual profit, vs $-146 for AGL. AGL carries lower financial leverage with a 0.29x debt-to-equity ratio, signaling a more conservative balance sheet compared to ASTH's 1.93x. On the Piotroski fundamental quality scale (0–9), ALHC scores 6/9 vs AGL's 2/9, reflecting solid financial health.
| Metric | |||||
|---|---|---|---|---|---|
| ROE (TTM)Return on equity | +4.9% | -146.0% | +11.5% | +6.2% | +11.5% |
| ROA (TTM)Return on assets | +1.5% | -24.5% | +1.8% | +2.2% | +3.9% |
| ROICReturn on invested capital | +6.2% | -2.0% | — | +4.1% | +9.2% |
| ROCEReturn on capital employed | +6.1% | -108.4% | +2.9% | +4.0% | +9.7% |
| Piotroski ScoreFundamental quality 0–9 | 3 | 2 | 6 | 5 | 6 |
| Debt / EquityFinancial leverage | 1.93x | 0.29x | 1.89x | 0.73x | 0.77x |
| Net DebtTotal debt minus cash | $649M | -$137M | -$240M | $8.7B | $54.0B |
| Cash & Equiv.Liquid assets | $429M | $174M | $578M | $4.2B | $24.4B |
| Total DebtShort + long-term debt | $1.1B | $37M | $338M | $12.9B | $78.4B |
| Interest CoverageEBIT ÷ Interest expense | 2.49x | -119.84x | 1.27x | 3.08x | 4.71x |
Total Returns (Dividends Reinvested)
ASTH leads this category, winning 3 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in ASTH five years ago would be worth $11,355 today (with dividends reinvested), compared to $648 for AGL. Over the past 12 months, ASTH leads with a +17.5% total return vs AGL's -32.6%. The 3-year compound annual growth rate (CAGR) favors ALHC at 35.4% vs AGL's -56.2% — a key indicator of consistent wealth creation.
| Metric | |||||
|---|---|---|---|---|---|
| YTD ReturnYear-to-date | +55.8% | +222.0% | -11.3% | +4.3% | +13.6% |
| 1-Year ReturnPast 12 months | +17.5% | -32.6% | +16.3% | +9.9% | +0.8% |
| 3-Year ReturnCumulative with dividends | +12.3% | -91.6% | +148.0% | -46.7% | -17.8% |
| 5-Year ReturnCumulative with dividends | +13.6% | -93.5% | -16.6% | -37.9% | -0.9% |
| 10-Year ReturnCumulative with dividends | +678.2% | -93.0% | +3.6% | +76.1% | +228.3% |
| CAGR (3Y)Annualised 3-year return | +4.0% | -56.2% | +35.4% | -18.9% | -6.3% |
Risk & Volatility
Evenly matched — ASTH and UNH each lead in 1 of 2 comparable metrics.
Risk & Volatility
UNH is the less volatile stock with a 0.60 beta — it tends to amplify market swings less than AGL's 3.07 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. ASTH currently trades 98.5% from its 52-week high vs AGL's 63.8% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | |||||
|---|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.10x | 3.07x | 0.81x | 0.61x | 0.60x |
| 52-Week HighHighest price in past year | $39.90 | $85.00 | $23.87 | $315.35 | $390.92 |
| 52-Week LowLowest price in past year | $18.08 | $0.97 | $11.63 | $163.11 | $234.60 |
| % of 52W HighCurrent price vs 52-week peak | +98.5% | +63.8% | +75.1% | +87.2% | +97.2% |
| RSI (14)Momentum oscillator 0–100 | 79.2 | 85.1 | 38.1 | 76.9 | 76.9 |
| Avg Volume (50D)Average daily shares traded | 490K | 383K | 3.6M | 1.6M | 7.9M |
Analyst Outlook
UNH leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
Analyst consensus: ASTH as "Buy", AGL as "Hold", ALHC as "Buy", HUM as "Hold", UNH as "Buy". Consensus price targets imply 38.5% upside for ALHC (target: $25) vs -14.7% for AGL (target: $46). For income investors, UNH offers the higher dividend yield at 2.29% vs ASTH's 0.41%.
| Metric | |||||
|---|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Hold | Buy | Hold | Buy |
| Price TargetConsensus 12-month target | $37.80 | $46.25 | $24.83 | $246.00 | $385.43 |
| # AnalystsCovering analysts | 10 | 25 | 16 | 44 | 52 |
| Dividend YieldAnnual dividend ÷ price | +0.4% | — | — | +1.3% | +2.3% |
| Dividend StreakConsecutive years of raises | 1 | — | — | 0 | 25 |
| Dividend / ShareAnnual DPS | $0.16 | — | — | $3.56 | $8.70 |
| Buyback YieldShare repurchases ÷ mkt cap | +0.7% | +0.3% | 0.0% | +0.5% | +1.6% |
UNH leads in 4 of 6 categories (Income & Cash Flow, Valuation Metrics). ASTH leads in 1 (Total Returns). 1 tied.
ASTH vs AGL vs ALHC vs HUM vs UNH: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is ASTH or AGL or ALHC or HUM or UNH a better buy right now?
For growth investors, Astrana Health, Inc.
(ASTH) is the stronger pick with 56. 4% revenue growth year-over-year, versus -2. 1% for Agilon Health, Inc. (AGL). Humana Inc. (HUM) offers the better valuation at 27. 9x trailing P/E (30. 8x forward), making it the more compelling value choice. Analysts rate Astrana Health, Inc. (ASTH) a "Buy" — based on 10 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — ASTH or AGL or ALHC or HUM or UNH?
On trailing P/E, Humana Inc.
(HUM) is the cheapest at 27. 9x versus Astrana Health, Inc. at 85. 4x. On forward P/E, UnitedHealth Group Incorporated is actually cheaper at 20. 7x — notably different from the trailing picture, reflecting expected earnings growth.
03Which is the better long-term investment — ASTH or AGL or ALHC or HUM or UNH?
Over the past 5 years, Astrana Health, Inc.
(ASTH) delivered a total return of +13. 6%, compared to -93. 5% for Agilon Health, Inc. (AGL). Over 10 years, the gap is even starker: ASTH returned +678. 2% versus AGL's -93. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — ASTH or AGL or ALHC or HUM or UNH?
By beta (market sensitivity over 5 years), UnitedHealth Group Incorporated (UNH) is the lower-risk stock at 0.
60β versus Agilon Health, Inc. 's 3. 07β — meaning AGL is approximately 415% more volatile than UNH relative to the S&P 500. On balance sheet safety, Agilon Health, Inc. (AGL) carries a lower debt/equity ratio of 29% versus 193% for Astrana Health, Inc. — giving it more financial flexibility in a downturn.
05Which is growing faster — ASTH or AGL or ALHC or HUM or UNH?
By revenue growth (latest reported year), Astrana Health, Inc.
(ASTH) is pulling ahead at 56. 4% versus -2. 1% for Agilon Health, Inc. (AGL). On earnings-per-share growth, the picture is similar: Alignment Healthcare, Inc. grew EPS 99. 4% year-over-year, compared to -55. 6% for Agilon Health, Inc.. Over a 3-year CAGR, ASTH leads at 40. 6% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — ASTH or AGL or ALHC or HUM or UNH?
UnitedHealth Group Incorporated (UNH) is the more profitable company, earning 2.
7% net margin versus -6. 8% for Agilon Health, Inc. — meaning it keeps 2. 7% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: UNH leads at 4. 2% versus -7. 1% for AGL. At the gross margin level — before operating expenses — UNH leads at 18. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is ASTH or AGL or ALHC or HUM or UNH more undervalued right now?
On forward earnings alone, UnitedHealth Group Incorporated (UNH) trades at 20.
7x forward P/E versus 101. 8x for Alignment Healthcare, Inc. — 81. 1x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for ALHC: 38. 5% to $24. 83.
08Which pays a better dividend — ASTH or AGL or ALHC or HUM or UNH?
In this comparison, UNH (2.
3% yield), HUM (1. 3% yield), ASTH (0. 4% yield) pay a dividend. AGL, ALHC do not pay a meaningful dividend and should not be held primarily for income.
09Is ASTH or AGL or ALHC or HUM or UNH better for a retirement portfolio?
For long-horizon retirement investors, UnitedHealth Group Incorporated (UNH) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.
60), 2. 3% yield, +228. 3% 10Y return). Agilon Health, Inc. (AGL) carries a higher beta of 3. 07 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (UNH: +228. 3%, AGL: -93. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between ASTH and AGL and ALHC and HUM and UNH?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: ASTH is a small-cap high-growth stock; AGL is a small-cap quality compounder stock; ALHC is a small-cap high-growth stock; HUM is a mid-cap quality compounder stock; UNH is a large-cap quality compounder stock. HUM, UNH pay a dividend while ASTH, AGL, ALHC do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.